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CLUSIONS: The levels of renal dysfunction and retinopathy are associ-
ated with a decrease in heart rate variability, especially LF components.
Combination of power spectral analysis and cardiac MIBG becomes a
powerful and interactive noninvasive assessment of autonomic nervous
dysfunction in patients with EHT.
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LOSARTAN BUT NOT IRBESARTAN REDUCES
SERUM URIC ACID IN HYPERTENSIVE PATIENTS
WITH HYPERURICEMIA AND/OR GOUT
Gre´goire Wuerzner, Arnaud Chiole´ro, Marc P. Maillard, Charles A.
Gerster, Michel Burnier. 1Division of Hypertension and Vascular
Medicine and Division of Rheumatology, Lausanne University
Hospital, Lausanne, Switzerland
Losartan has unique uricosuric properties and has been shown to decrease
serum uric acid (SUA) levels in normal subjects as well as in hyperten-
sive patients. The purpose of the present study was to compare the effects
of losartan and irbesartan on serum uric acid in hypertensive hyperuri-
cemic patients with or without gout.
Twelve hyperuricemic (SUA.420mmol/L), hypertensive patients
(mean age: 58 yr) participated in this randomized, double-blind, cross-
over study. After a 3-week run-in period during which patients received
enalapril 20 mg o.d, patients were randomized to receive either losartan
50 mg o.d for 4 weeks followed by losartan 50 mg bid for another 4 week
period or irbesartan 150 mg o.d followed by irbesartan 150 mg bid for 4
weeks. The losartan and irbesartan phases were separated by 3 weeks of
the ACE inhibitor. All drugs were provided in an electronic pill container
allowing to monitor compliance (MEMS system).
Losartan decreased SUA significantly from 539628 mmol/L to
490622 mmol/L (p,0.01) at 50 mg od and to 482628 mmol/L at 50 mg
bid, in contrast to irbesartan which had no effect on SUA. The first dose
of losartan increased the urinary uric acid/creatinine ratio during the first
4h after drug intake, when compared with irbesartan (0.54560.074 vs
0.36160.049, p50.016). This increase was still present at week 4
(0.49460.092 vs 0.33260.062, p,0.01) but was not found at week 8
when patients received a bid regimen (0.28460.031 vs
0.32960.032,p5ns). The monitoring of compliance showed that the
adherence to the morning dose was good (90.461.7%) and significantly
greater than that to the evening dose (81.3062.2%, p,0.001). The
changes in blood pressure induced by losartan and irbesartan were
comparable.
These results demonstrate the potential benefits of using losartan in
hypertensive patients with hyperuricemia and gout. They also suggest
that losartan-treated patients reach a new uric acid steady-state during a
sustained administration (.1 month). Hence, the uricosuric effect tends
to decrease with time as SUA is reduced. Increasing the dose of losartan
to 50 mg bid does not appear to induce a further decrease in serum uric
acid.
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REDUCTION OF BLOOD PRESSURE FROM CALCIUM
SUPPLEMENTATION IN ADOLESCENT PREGNANCY:
A RANDOMIZED TRIAL
Jorge A. Prada, Reginald C. Tsang, Shumei Guo. 1Pediatrics, Division
of Nephrology & Hypertension, Children’s Hospital Medical Center,
Cincinnati, OH, United States, 2Pediatrics, Division of Neonatology,
Children’s Hospital Medical Center, Cincinnati, OH, United States,
3Community Health, Wright State University, Dayton, OH, United
States
The incidence of gestational hypertension in adolescents less than 16
years of age is 3 times of that reported in the singleton pregnant adult.
From previous mostly non-US investigations it appeared that calcium
supplementation during pregnancy may decrease blood pressure and
reduce the incidence of pregnancy-induced hypertension (PIH) and pre-
eclampsia. However, a recent US multicenter clinical trial of calcium
supplementation to prevent preeclampsia demonstrated no protective
effect in normal pregnant adults. These contradictory studies could in
theory be related to differences in basal dietary calcium intakes in diverse
countries. We chose the high risk population of pregnant teens wherein
there may be a theoretic increased need for calcium during pregnancy, to
test the calcium supplementation hypothesis in a US high risk population.
We randomized 124 healthy pregnant teenagers into a calcium sup-
plementation trial of 1000 mg/day of calcium or placebo by 20 weeks of
gestation and followed them until delivery. In the trial, 62 “high risk”
pregnant adolescents on calcium supplementation were compared to 62
“high risk” pregnant teens on placebo supplementation. Blood pressure
measurements were conducted throughout pregnancy at each scheduled
study visit. Blood samples were collected to study calcium metabolism.
There were no differences in age, 16.9 6 1.4 years for adolescents on
calcium and 16.7 6 1.5 years for adolescents on placebo; nor height or
weight at enrollment 161.9 6 4.2 cm, and 67.2 6 12.2 kg on calcium and
162.4 6 5.8 cm and 70.6 6 19.5 kg on placebo, respectively. There were
no differences in daily consumption of calcium from the diet 976 6 342
mg/day and 990 6 366 mg/day respectively; nor plasma ionized calcium,
4.98 6 0.16 mg/dL and 4.94 6 0.14 mg/dL respectively. Parathyroid
hormone, (PTH) was reduced on calcium 15.5 6 9.2 ng/dL and 21.3 6
10.8 ng/mL (P 5 0.05) respectively. Calcitriol was reduced on calcium
but did not reach significance, 75.1 6 26.1 pg/dL and 81.6 6 38.3 pg/dL
(P 5 0.06) respectively.
Systolic and diastolic blood pressures at 36 weeks of gestation were
significantly lower (P 5 0.05) in subjects receiving calcium Vs placebo:
systolic blood pressure 120.7 6 9.8 mmHg Vs 125.1 6 9.3 mmHg,
diastolic to 67.5 6 6.5 Vs 70.2 66.8 mmHg, respectively. Mean blood
pressure was significantly lower (P 5 0.05) in adolescents receiving
calcium 85.2 6 7.6 mmHg Vs placebo 88.5 6 6.6 mmHg.
Calcium supplementation significantly reduces the systolic and dia-
stolic blood pressures in the USA of a high risk pregnant population,
adolescents with singleton gestations.
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ANGIOTENSIN II DOES NOT AFFECT FIBRINOLYTIC
FUNCTION IN HEALTHY SUBJECTS
Katja Lottermoser, Hans-Joerg Hertfelder, Beate Schiermeyer, Hans
Vetter, Rainer Duesing. 1Internal Medicine, Medizinische Universita¨ts-
Poliklinik, Bonn, Germany
Numerous experimental studies have provided evidence for a direct
functional link between the renin-angiotensin-aldosterone-system-
(RAAS) and the fibrinolytic system. Angiotensin II (AII)has been sug-
gested to mediate this interrelationship because this peptide was shown to
stimulate plasminogen activator inhibitor-1 (PAI-1) in various tissues in
vitro and in experimental animals in vivo. While an early study had
revealed increased PAI-1 concentrations following AII infusion in a
small number of healthy volunteers and in hypertensive patients, more
recent infusion studies in man could not support these data. In the present
study, we have therefore used AII at doses of 1,3 and 10 ng kg-1min-1,
each over 45 min., in 9 healthy volunteer subjects with and without
pre-treatment with a single dose of the angiotensin II(type 1)(AT1)-
receptor antagonist Valsartan (160 mg). All infusion increased arterial
blood pressure from 12166/816mmHg to 15368/10165 mmHg
(p,0.001). Over the time period investigated (11.00 AM-02.45 PM,
plasma concentrations and activities of PAI-1 tended to decrease while
the corresponding values for the tissue plasminogen activator (t-PA)
tended to change in the opposite direction. In spite of the marked
hemodynamic changes seen with the AII infusion, no effect could be
demonstrated on the measured parameters of fibrinolytic function. Fur-
thermore, pre-treatment of the volunteers with the AT1-receptor antago-
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